BioMarin Pharmaceutical Inc. (BMRN) stock is down -35.44% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives BMRN stock a score of 27 out of a possible 100.
That rank is influenced by a short-term technical score of 12. BMRN's rank also includes a fundamental score of 26. In addition to the average rating from Wall Street analysts, BMRN stock has a mean target price of $106.20. This means analysts expect the stock to gain 37.28% over the next 12 months. The long-term technical score for BMRN is 43.
BMRN has an Overall Score of 27. Find out what this means to you and get the rest of the rankings on BMRN!
BioMarin Pharmaceutical Inc. (BMRN) stock is up 1.2% while the S&P 500 has risen 0.33% as of 1:06 PM on Thursday, Aug 5. BMRN has risen $0.92 from the previous closing price of $76.44 on volume of 418,594 shares. Over the past year the S&P 500 has gained 32.74% while BMRN is down -35.44%. BMRN earned $4.26 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 18.18.
Click Here to get the full Stock Report for BioMarin Pharmaceutical Inc. stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
